| Name | ARN2966 |
| Description | ARN2966 is an inhibitor of amyloid precursor protein (APP)and amyloid-β (Aβ) secretion. |
| In vitro | ARN2966 reduces levels of APP and its intracellular C-terminal fragments α-CTF and β-CTF in CHO APP751SW cells when used at a concentration of 10 μM. ARN2966?also reduces?secretion of Aβ (1-40) and Aβ (1-42) by 88.6 and 84.9%, respectively. |
| In vivo | In vivo,ARN2966? reduces brain levels of full-length APP, α-CTF and β-CTF, and soluble Aβ (1-40) and Aβ (1-42) in the APPSWPS1dE9 transgenic mouse model of Alzheimer's disease.?It also improves novel object memory as well as spatial memory in the radial arm maze in APPSWPS1dE9 transgenic mice. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 55 mg/mL (274.67 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (9.99 mM), Sonication is recommended.
|
| Keywords | β-amyloid peptide | βAmyloid | β Amyloid | Inhibitor | inhibit | BetaAmyloid | Beta Amyloid | bAmyloid | b Amyloid | ARN-2966 | ARN2966 | ARN 2966 | Amyloid-β | Abeta |
| Inhibitors Related | Benzenesulfonamide | Deferoxamine Mesylate | Cromolyn sodium | HEPPS | Phytic acid sodium salt | Rutin | Resveratrol | 10-Undecenoic acid | 2,4-Di-tert-butylphenol | Chlorzoxazone | Methyl tridecanoate | Glimepiride |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Anti-Alzheimer's Disease Compound Library | Neuroprotective Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Preclinical Compound Library |